Advertisement
UK markets close in 8 hours 2 minutes
  • FTSE 100

    8,436.58
    +16.32 (+0.19%)
     
  • FTSE 250

    20,804.72
    +54.82 (+0.26%)
     
  • AIM

    807.64
    +13.62 (+1.72%)
     
  • GBP/EUR

    1.1669
    -0.0009 (-0.08%)
     
  • GBP/USD

    1.2692
    -0.0014 (-0.11%)
     
  • Bitcoin GBP

    52,533.30
    -434.70 (-0.82%)
     
  • CMC Crypto 200

    1,360.51
    +6.09 (+0.45%)
     
  • S&P 500

    5,303.27
    +6.17 (+0.12%)
     
  • DOW

    40,003.59
    +134.19 (+0.34%)
     
  • CRUDE OIL

    80.22
    +0.16 (+0.20%)
     
  • GOLD FUTURES

    2,444.30
    +26.90 (+1.11%)
     
  • NIKKEI 225

    39,069.68
    +282.30 (+0.73%)
     
  • HANG SENG

    19,622.90
    +69.29 (+0.35%)
     
  • DAX

    18,732.71
    +28.29 (+0.15%)
     
  • CAC 40

    8,176.18
    +8.68 (+0.11%)
     

Correction to Company announcement – No. 23 / 2024

Zealand Pharma
Zealand Pharma

Correction to Company announcement – No. 23 / 2024

Copenhagen, Denmark, April 19, 2024 Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has a correction to company announcement No. 23 /2024, April 19, 2024 - regarding transactions in Zealand’s shares or related securities conducted by persons discharging managerial responsibilities and/or their closely associated persons it was reported that member of the management, Henriette Wennicke, was allocated a total of 8,008 restricted stock units with a total value of DKK 9,577,568.00.

The correct number was a total of 8,008 restricted stock units with a total value of DKK 4,788,784.00.

ADVERTISEMENT

Please see the attached file(s).

# # #

About Zealand Pharma A/S

Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. The company has development partnerships with a number of pharma companies as well as commercial partnerships for its marketed products.

Zealand was founded in 1998 and is headquartered in Copenhagen, Denmark, with a presence in the U.S. For more information about Zealand’s business and activities, please visit www.zealandpharma.com.

Contact:

Adam Lange
Investor Relations Officer
Zealand Pharma
Email: alange@zealandpharma.com

Anna Krassowska, PhD
Vice President, Investor Relations & Corporate Communications
Zealand Pharma
Email: akrassowska@zealandpharma.com

Attachment